Perspective Therapeutics, Inc. (CATX) Stock
Key stats
- Market cap
- $99.65M
- Price / Earnings ratio
- -0.8x
- EPS (TTM)
- -$1.25
- Volume
- Loading
- 52-week high
- $6.16
- 52-week low
- $0.78
Source: third-party data provider, as of November 13, 2026
Compare with CATX
Recent news

Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
CATX

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
CATX

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
CATX

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CATX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 22.79
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.43
- MACD histogram
- -0.02
- SMA 50
- $2.20
- Price below SMA 50
- EMA 50
- $1.97
- Price below EMA 50
- SMA 200
- $3.47
- Price below SMA 200
- EMA 200
- $2.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
CATX

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
CATX

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
CATX

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CATX

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
CATX

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
CATX

Insider Trading is Good News for These Stocks
Insider Trading is Good News for These Stocks
CATX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Perspective Therapeutics, Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Johan M. Spoor | CEO & Director | 1972 |
| Mr. Joel David Sendek | CFO & Principal Financial Officer | 1967 |
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer | 1966 |
| Dr. Michael K. Schultz Ph.D. | Co-Founder & Senior Scientific Advisor | — |
| Mr. Shane Cobb | Executive Vice President of Operations | — |
| Mr. Jonathan R. Hunt | Chief Accounting Officer | 1967 |
| Dr. Paul Lyne Ph.D. | Chief Science Officer | — |
| Ms. Annie J. Cheng | Vice President of Investor Relations | 1976 |
| Mr. Chris Nenno | General Counsel & Corporate Secretary | — |
| Mr. Andrew Bright | Executive Vice President of Brachytherapy | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 22.79
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.43
- MACD histogram
- -0.02
- SMA 50
- $2.20
- Price below SMA 50
- EMA 50
- $1.97
- Price below EMA 50
- SMA 200
- $3.47
- Price below SMA 200
- EMA 200
- $2.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $8.14
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -3.9 | +74.8 | -9.9 | -13.7 | +26.5 | -17.3 | -30.2 | -32.3 | -4.1 | -3.0 | +54.6 | |
| 2024 | +102.0 | +10.7 | +25.4 | +31.3 | -18.8 | -27.2 | +21.4 | +17.9 | -5.9 | -6.5 | -64.0 | -23.1 |
| 2025 | +7.3 | -15.8 | -13.4 | +25.0 | +4.0 | +43.9 | +17.1 | -8.7 | +3.3 | -20.4 | -9.6 | +25.6 |
| 2026 | +35.8 | +6.7 | -22.1 | -11.8 | +2.3 | -6.8 | -15.9 | +5.0 | -11.3 | -57.7 | -20.2 |



